Literature DB >> 7531125

Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis.

L Lepore1, M Pennesi, S Saletta, S Perticarari, G Presani, M Prodan.   

Abstract

In the last few years the important role played by various cytokines in the pathogenesis of chronic inflammatory diseases has emerged. In the present study, serum and synovial fluid levels of IL-2, IL-6, TNF alpha, IFN beta and IFN gamma were evaluated in a group of 66 patients with juvenile chronic arthritis (JCA). At the same time the ESR, CRP, hemoglobin, immunoglobulins, platelet count and Ritchie index were measured. In the serum of pauciarticular patients, IL-6 and TNF alpha levels were only slightly elevated compared with controls, but there was no correlation between these cytokines and clinical and other laboratory parameters. Serum IL-2 and IFN gamma were undetectable. In contrast, in the synovial fluid IL-6 levels were very high in all of the patients examined and there was a significant correlation between synovial fluid IL-6 levels and Ritchie's articular index. TNF alpha tended to be elevated but to a lesser extent, while synovial fluid IL-2 and IFN gamma were undetectable or very low, as in the serum. In polyarticular and systemic patients, on the other hand, serum IL-6 was elevated and statistically correlated with the majority of the laboratory parameters and with the Ritchie articular index. TNF alpha levels were only slightly elevated; on the other hand, IL-2 and IFN gamma were undetectable. There was an inverse correlation between IFN beta levels and the Ritchie articular index and a significant correlation with hemoglobin levels. In conclusion, our study demonstrates that not only IL-1 (as shown in other studies), but also IL-6 and to a lesser extent TNF alpha play a central role in the pathogenesis of JCA. IFN beta on the other hand, would seem to play an anti-inflammatory role.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531125

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  23 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 3.  The use of anakinra in juvenile arthritis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

Review 4.  A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

Authors:  Andrea Rubbert-Roth; Daniel E Furst; Jan Michael Nebesky; Angela Jin; Erhan Berber
Journal:  Rheumatol Ther       Date:  2018-03-03

5.  Cytokines and juvenile idiopathic arthritis.

Authors:  Patricia Woo
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

6.  Cytomegalovirus infection in pediatric rheumatic diseases: a review.

Authors:  Eli M Eisenstein; Dana G Wolf
Journal:  Pediatr Rheumatol Online J       Date:  2010-05-20       Impact factor: 3.054

7.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15

8.  T cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis.

Authors:  K Jiang; Y Chen; C-S Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

9.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

10.  Challenges in the management of juvenile idiopathic arthritis with etanercept.

Authors:  Clare E Pain; Liza J McCann
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.